Clinical Trial

Electronic Data Capture Software Market is expected to generate a revenue of USD 4.06 Billion by 2031, Globally, at 14.5% CAGR: Verified Market Research®

The Electronic Data Capture Software Market is witnessing robust growth driven by the rising demand for decentralized clinical trials, real-time…

1 month ago

Pharmaceutical Quality Management Software Market worth $2.98 billion by 2030 with 13.3% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Nov. 17, 2025 /PRNewswire/ -- The global Pharmaceutical Quality Management Software Market, valued at US$1.41 billion in 2024,…

1 month ago

WCG CenterWatch Unveils Benchmarking Report Assessing AI Adoption in Clinical Research

CARY, N.C., Nov. 17, 2025 /PRNewswire/ -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical…

1 month ago

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage…

1 month ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Presenting INTASYL siRNA Drug TechnologyKing of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is…

1 month ago

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established…

1 month ago

NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has…

1 month ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~ SAN DIEGO, CA /…

1 month ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure…

1 month ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health…

1 month ago